A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NASH / nonalcoholic steatohepatitis

[Related PubMed/MEDLINE]
Total Number of Papers: 5182
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NASH  (>> Co-occurring Abbreviation)
Long Form:   nonalcoholic steatohepatitis
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. ELA
2020 A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. HSCs, MCD, TAA
2020 A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. CCK, CCKRs, CDE, HCC
2020 A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. NAFLD
2020 A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. LSECs
2020 A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. ADA, RCTs
2020 A Microphysiological System for Studying Nonalcoholic Steatohepatitis. MPS, NAFLD, PNPLA3
2020 A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. CVC, TXR
2020 A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. HCC, MRI, NAFLD
10  2020 Ablation of Hmgb1 in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice. apoB48, CHO, CM, HMGB1, IEC, SR-B1, TG
11  2020 Adaptive immunity: an emerging player in the progression of NAFLD. HCC, NAFLD
12  2020 AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review. BPA, HCC, NAFLD
13  2020 Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway. HFD, LPS, MAPK, NAFLD, QHD
14  2020 Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. ASMase, HP-HFD, LPS, PA, S1P
15  2020 An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. AMP
16  2020 An obese patient with acute cholecystitis, nonalcoholic steatohepatitis and cirrhosis: A case report. ---
17  2020 Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy. ALT, AST, circRNAs, MCD
18  2020 Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition. AQP9, NAFLD
19  2020 Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. MS, NAFLD, SAT, VAT
20  2020 Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. NAFLD, RR
21  2020 Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. HFpEF, NAFLD
22  2020 Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis. BA, FFA, NLRP3
23  2020 Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. DIAMOND
24  2020 Bile Acid Sequestration Reverses Liver Injury and Prevents Progression of NASH in Western Diet-Fed Mice. BAS, NAFLD
25  2020 Biomarker discovery for chronic liver diseases by multi-omics - a preclinical case study. ---
26  2020 C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. CI, NAFLD, ORs
27  2020 Carbon monoxide releasing molecule-A1 improves nonalcoholic steatohepatitis via Nrf2 activation mediated improvement in oxidative stress and mitochondrial function. ARE, CORM-A1, HFHF, Nrf2, PA, ROS
28  2020 Cathepsin-B dependent autophagy ameliorates steatoheaptitis in chronic exercise rats. CYP2E1, HFD, ROS
29  2020 Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. CDS, GSD, HCV, NAFLD
30  2020 CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis. NAFLD
31  2020 CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. HSC
32  2020 Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. CVC
33  2020 Challenges and opportunities in drug development for nonalcoholic steatohepatitis. NAFLD
34  2020 Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. IHTG, MRI
35  2020 Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. HBV, HCV, NAFLD, T2D
36  2020 Characterization of Human Induced Pluripotent Stem Cell-Derived Hepatocytes with Mature Features and Potential for Modeling Metabolic Diseases. hiPS-HEP, LDL, TNF-alpha
37  2020 Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. MVBs, NAFLD
38  2020 Cigarette smoking differentially regulates inflammatory responses in a mouse model of nonalcoholic steatohepatitis depending on exposure time point. CS, MSCS, PPARgamma
39  2020 CircularRNA as novel biomarkers in liver diseases. circRNA, HCC, miRNA, NAFLD
40  2020 Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism. SB, TG
41  2020 Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. CDAA, HCC, MCD
42  2020 Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. ASH, HCC
43  2020 Complications, morbidity and mortality of nonalcoholic fatty liver disease. NAFLD, T2DM
44  2020 Computational Insight into Allosteric Activation Mechanism of Farnesoid X Receptor. CDCA, FXR
45  2020 Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis. NAFL, NAFLD
46  2020 Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver. CAS, CCTA, DLP, NAFLD
47  2020 CRLS1 ameliorates nonalcoholic steatohepatitis through ATF3 transcriptional inactivation. ATF3, CRLS1, HFD, HFHC
48  2020 Current management of non-alcoholic steatohepatitis. ---
49  2020 Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). ---
50  2020 Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications. ALD, ER, ERAD, ERAD, NAFLD, UPD
51  2020 Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease. A-INS, AUROC, NAFLD, ROC
52  2020 Development of new drugs for the treatment of nonalcoholic steatohepatitis. ---
53  2020 Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. hrNASH, SWE
54  2020 Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. DPP-4, HCC
55  2020 Discovery of Novel Peroxisome Proliferator-Activated Receptor alpha (PPARalpha) Agonists by Virtual Screening and Biological Evaluation. LBD, MD, PPARalpha
56  2020 Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis. HFCF, SHP
57  2020 Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast. FXR, sEH
58  2020 Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity. PINK1, ROS, SFA
59  2020 Dysregulated FXR-FGF19 Signaling and Choline Metabolism is Associated with Gut Dysbiosis and Hyperplasia in a Novel Pig Model of Pediatric NASH. BA, FXR
60  2020 Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. NAFLD, T2DM
61  2020 Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals. NAFLD, PNPLA3
62  2020 Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high-fat, high-cholesterol diet. HFHCD, YZH
63  2020 Effects of (-)-epicatechin on the time course of the expression of perilipins in a diet-induced model of nonalcoholic steatohepatitis. EC, PD, TG
64  2020 Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. NAFLD, RCT, T2DM
65  2020 Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model. ---
66  2020 Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). NAFLD, PPARs
67  2020 Emerging therapeutic targets for NASH: key innovations at the preclinical level. BMP, DNL, ER
68  2020 Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. SGLT2, T2DM
69  2020 Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents. MRE, MRI, NAFLD, PDFF
70  2020 Explant liver evaluation decodes the mystery of cryptogenic cirrhosis! AI
71  2020 Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model. ACC, DNL, FXR
72  2020 Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice. GPX4, MCD
73  2020 FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. AST, CAP, FAST, LSM, NAFLD, NPV, PPV
74  2020 Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH). SP, SS
75  2020 Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. FOS, MSG, NAFLD
76  2020 GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. AFP, AFP-L3, AUC, DCP, HCC
77  2020 Glyphosate Excretion is Associated With Steatohepatitis and Advanced Liver Fibrosis in Patients With Fatty Liver Disease. NAFLD
78  2020 GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). ACC, DNL
79  2020 Gut microbial fatty acid metabolites (KetoA and KetoC) affect the progression of nonalcoholic steatohepatitis and reverse cholesterol transport metabolism in mouse model. HFD
80  2020 Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis. ALR, HF/HC, NAFLD
81  2020 Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? NAFLD, SCI
82  2020 Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. FATP5, NAFLD
83  2020 Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. CTP, HCC, HCV, MELD, NAFLD
84  2020 Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. HCC
85  2020 Hepatocellular Carcinoma Risk in Patients With NASH Cirrhosis and Diabetes: Insufficient for Individual Management. HCC
86  2020 Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. HCC, MCL1
87  2020 Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. ASK1, HSC, Lys6, TRAF6
88  2020 Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. NAFLD, THM
89  2020 High fructose-containing drinking water-induced steatohepatitis in rats is prevented by the nicotinamide-mediated modulation of redox homeostasis and NADPH-producing enzymes. G6PD, ME, NAM
90  2020 HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis. EVs, HLSCs
91  2020 How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. NAFLD
92  2020 Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. PPAR-alpha
93  2020 Identification of hub genes and key pathways of dietary advanced glycation end products‑induced non‑alcoholic fatty liver disease by bioinformatics analysis and animal experiments. AGEs, CAMs, DEGs, NAFLD
94  2020 Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis. ALP, NAS, OR
95  2020 Imbalanced insulin substrate-1 and insulin substrate-2 signaling trigger hepatic steatosis in vitamin D deficient rats: 8-methoxypsoralen, a vitamin D receptor ligand with a promising anti-steatotic action. 8-MOP, FOXO1, IRS2, NAFLD, VDD
96  2020 IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. NAFLD, NAS, SAF, T2DM
97  2020 Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. LT, NAFLD
98  2020 In Vitro Production of Human Ballooned Hepatocytes in a Cell Sheet-based Three-dimensional Model. BH, MDBs
99  2020 Increased Frequency of Heterozygous Alpha-1-Antitrypsin Deficiency in Liver Explants From Nonalcoholic Steatohepatitis Patients. A1AT, A1ATD, IHC, PASD
100  2020 Inhibition of Grb14, a negative modulator of insulin signaling, improves glucose homeostasis without causing cardiac dysfunction. DIO, IR, KO, T2D